Pulmonary hypertension in eosinophilic versus noneosinophilic COPD
- PMID: 33718496
- PMCID: PMC7938054
- DOI: 10.1183/23120541.00772-2020
Pulmonary hypertension in eosinophilic versus noneosinophilic COPD
Abstract
Background: The eosinophilic COPD phenotype is associated with greater airway remodelling, exacerbation risk and steroid responsiveness. However, little is known about the prevalence and characteristics of pulmonary hypertension (PH) in this patient population.
Methods: We retrospectively evaluated a cohort of COPD patients with right heart catheterisation (RHC) data at a university hospital between January 2011 and May 2019 and compared the pulmonary vascular profile and prevalence of PH between eosinophilic and noneosinophilic patients using a definition of eosinophilic COPD as at least three blood eosinophil values ≥300 cells·µL-1. We used multivariable logistic regression analyses to examine the association between eosinophilic COPD and various PH categories adjusting for age, sex, body mass index, forced expiratory volume in 1 s (%), smoking status and use of supplemental oxygen.
Results: Among 106 COPD patients with RHC data and at least three blood eosinophil values, 25% met the definition of eosinophilic COPD. Fewer patients among the eosinophilic group required long-term oxygen therapy (69% versus 93%, p=0.001) and total lung capacity was significantly lower in the eosinophilic group (p=0.006). This group had higher mean pulmonary arterial pressure (mPAP) (median (interquartile range) 30 (27-41) mmHg versus 25 (22-30) mmHg, p=0.001) and pulmonary vascular resistance (PVR) (4 (2.8-5.1) Wood units versus 2.9 (2.1-4.1) Wood units, p=0.018). On multivariable logistic regression analyses, eosinophilic phenotype was associated with PH (adjusted (a)OR 6.5, 95% CI 1.4-30.7; p=0.018) and pre-capillary PH (aOR 3.2, 95% CI 1.1-9; p=0.027), but not severe PH (aOR 2.1, 95% CI 0.6-7.2; p=0.219).
Conclusion: Eosinophilic COPD was associated with higher mPAP and PVR and increased likelihood of PH. More studies are needed to further explore this finding.
Copyright ©The authors 2021.
Conflict of interest statement
Conflict of interest: B.N. Alzghoul has nothing to disclose. Conflict of interest: M. As Sayaideh has nothing to disclose. Conflict of interest: B.F. Moreno has nothing to disclose. Conflict of interest: S.K. Singh has nothing to disclose. Conflict of interest: A. Innabi has nothing to disclose. Conflict of interest: R. Reddy has nothing to disclose. Conflict of interest: E.S. Papierniak has nothing to disclose. Conflict of interest: H.M. Alnuaimat has nothing to disclose.
Figures
Similar articles
-
Pulmonary hypertension in chronic lung diseases.J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036. J Am Coll Cardiol. 2013. PMID: 24355635 Review.
-
Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization.Int J Cardiol Heart Vasc. 2020 Apr 21;28:100513. doi: 10.1016/j.ijcha.2020.100513. eCollection 2020 Jun. Int J Cardiol Heart Vasc. 2020. PMID: 32346602 Free PMC article.
-
Long-term oxygen treatment need is less frequent in eosinophilic COPD patients.Clin Respir J. 2022 Jan;16(1):49-56. doi: 10.1111/crj.13451. Epub 2021 Oct 26. Clin Respir J. 2022. PMID: 34626077 Free PMC article.
-
Clinical evaluation of pulmonary quantitative computed tomography parameters for diagnosing eosinophilic chronic obstructive pulmonary disease: Characteristics and diagnostic performance.Health Sci Rep. 2024 Mar 17;7(3):e1734. doi: 10.1002/hsr2.1734. eCollection 2024 Mar. Health Sci Rep. 2024. PMID: 38500635 Free PMC article.
-
Pulmonary Vasodilator Therapy in Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (Severe PH-COPD): A Systematic Review and Meta-Analysis.J Cardiovasc Dev Dis. 2023 Dec 16;10(12):498. doi: 10.3390/jcdd10120498. J Cardiovasc Dev Dis. 2023. PMID: 38132665 Free PMC article. Review.
Cited by
-
Current Blood Eosinophilia Does Not Predict the Presence of Pulmonary Hypertension in Patients with End-Stage Lung Disease.J Clin Med. 2025 Feb 9;14(4):1120. doi: 10.3390/jcm14041120. J Clin Med. 2025. PMID: 40004650 Free PMC article.
-
COPD associated pulmonary hypertension: A post hoc analysis of the PERFECT study.Pulm Circ. 2024 Oct 2;14(4):e12430. doi: 10.1002/pul2.12430. eCollection 2024 Oct. Pulm Circ. 2024. PMID: 39364449 Free PMC article.
-
Eosinophils protect against pulmonary hypertension through 14-HDHA and 17-HDHA.Eur Respir J. 2023 Mar 2;61(3):2200582. doi: 10.1183/13993003.00582-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36423907 Free PMC article.
References
-
- World Health Organization (WHO). Global Health Estimates. www.who.int/healthinfo/global_burden_disease/en/ Date last accessed: 31 August 2020.
-
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2020. Available from: www.goldcopd.org/ - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous